Clinical trial
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
NCT00075439 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00075439 |
|---|---|
| Title | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
| Official title | A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma, WDHA Syndrome |
| Intervention type | Drug, Other |
| Interventions | gefitinib, laboratory biomarker analysis |
| Enrollment | 90 |
| Start date | Dec 1, 2003 |
| Primary completion | May 1, 2007 |
| First posted | Jan 12, 2004 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: